ASH2010慢性髓性白血病12-10-2.ppt

慢性髓性白血病研究进展--第52届ASH会议重点解读 December 4-7, 2010 Orlando, FL 伊马替尼（400mg/d）是初诊CML慢性期患者的标准治疗 IRIS 8年随访结果EFS、无加速/急变生存率分别是82%、92% TKI治疗大大降低CML死亡率 部分患者仍存在耐药和疾病进展 第二代TKI治疗伊马替尼耐药的CML-CP患者，仅50%获CCyR，加速期患者获得CCyR率更低 The Phase 3 DASISION study compares dasatinib with imatinib as initial treatment for pts with newly diagnosed CML-CP. Eighteen-mo follow-up data are presented here 519 pts with newly diagnosed CML-CP (median disease duration of 1 mo) stratified by Hasford risk were randomized to either dasatinib 100 mg once daily (n = 259), or imatinib 400 mg once daily (n = 260). After 18 mos of foll